Mice bred to carry germline Rb and p53 null alleles are associated with a tumor spectrum that overlaps with the inherited multiple endocrine neoplasia-1 (MEN1) and MEN2 syndromes in humans, including medullary thyroid cancer (MTC). To study the genetic basis for these tumors, we microdissected MTC specimens or obtained fresh MTC tissue from nine independent Rb+/7 p53+/7 mice, ampli®ed the region of the Ret gene known to be mutated in human MTC, and detected acquired missense Ret mutations in four dierent mice. These mutations were localized to a group of tandem cysteines which are analogous to activating germline mutations observed in human MEN2A and familial MTC (FMTC). To determine whether the remaining wild type Rb allele was inactivated in these murine MTC samples, we subjected tumor tissue to immunohistochemical staining with an Rb antibody, and demonstrated the absence of RB staining in murine MTC, while normal tissue retained RB nuclear staining. These ®ndings demonstrate the ability of the gene knockout model to recapitulate somatic multi-step tumorigenesis and suggest that the development of a murine neuroendocrine tumor requires mutational dysregulation within both receptor tyrosine kinase and nuclear tumor suppressor gene pathways. Keywords: mouse model; p53; RB; Ret; thyroid cancer Neuroendocrine tumors arise from; (i) a collection of endocrine organs including the adrenal, parathyroid, thyroid, pineal and pituitary glands; (ii) a diuse endocrine system made up of the pancreatic islets of Langerhans, bronchial neuroepithelial bodies, and gastrointestinal endocrine cells, and (iii) neurosecretory neurons and paraganglia (Erlandson and Nesland, 1994; Kloppel and Heitz, 1994) . Although this heterogeneous system is de®ned by histological and biochemical properties, clinical and genetic studies of inherited cancer syndromes have provided a more selective classi®cation. For example, the multiple endocrine neoplasia (MEN) syndromes are characterized by a familial predisposition to a series of otherwise distinct endocrine tumors that exhibit speci®c clinical and pathological patterns. MEN1 patients develop pituitary, parathyroid, and endocrine (islet cell) pancreatic tumors, while aected MEN2 family members show a susceptibility to medullary thyroid cancer (MTC), adrenal pheochromocytoma, and parathyroid hyperplasia and tumors Smith et al., 1994) . While these observations suggest a genetic classi®cation for neuroendocrine tumors, the etiologic cellular pathways underlying the development of these inherited and sporadic tumors are still unde®ned.
Neuroendocrine tumors arise from; (i) a collection of endocrine organs including the adrenal, parathyroid, thyroid, pineal and pituitary glands; (ii) a diuse endocrine system made up of the pancreatic islets of Langerhans, bronchial neuroepithelial bodies, and gastrointestinal endocrine cells, and (iii) neurosecretory neurons and paraganglia (Erlandson and Nesland, 1994; Kloppel and Heitz, 1994) . Although this heterogeneous system is de®ned by histological and biochemical properties, clinical and genetic studies of inherited cancer syndromes have provided a more selective classi®cation. For example, the multiple endocrine neoplasia (MEN) syndromes are characterized by a familial predisposition to a series of otherwise distinct endocrine tumors that exhibit speci®c clinical and pathological patterns. MEN1 patients develop pituitary, parathyroid, and endocrine (islet cell) pancreatic tumors, while aected MEN2 family members show a susceptibility to medullary thyroid cancer (MTC), adrenal pheochromocytoma, and parathyroid hyperplasia and tumors Smith et al., 1994) . While these observations suggest a genetic classi®cation for neuroendocrine tumors, the etiologic cellular pathways underlying the development of these inherited and sporadic tumors are still unde®ned.
To investigate the genetic basis for neuroendocrine tumors we studied a murine model with targeted germline mutations within both the Rb and p53 genes that was recently shown to be associated with an increased incidence of selected endocrine tumors (Harvey et al., 1995; Williams et al., 1994) . We mated strain 129 Rb+/7 mice with strain 129 p53+/7 mice (obtained from Jackson Laboratories, Bar Harbor, ME, USA) to generate Rb/p53 double heterozygous and Rb heterozygous p53 homozygous ospring. Analysis of the tumor spectrum in Rb/p53 double heterozygous mice showed a high incidence of endocrine tumors including pituitary tumors (approximately 80%), multifocal pancreatic islet cell hyperplasia or tumors (17%), and multifocal thyroid C-cell hyperplasia or MTC (40%) (Figure 1a ). We also observed neuroendocrine tumors in our Rb heterozygous, p53 homozygous mice, with a 23% incidence of pituitary adenomas, a 40% incidence of pancreatic islet cell tumors or hyperplasia, and an 8% incidence of medullary thyroid carcinoma ( Figure  1b) .
To investigate the molecular basis for the unexpected development of MTC in these mice, we examined the status of the murine Ret gene in these tumor samples. The RET product is a receptor tyrosine kinase that transduces external signals required for the proper development of neural and renal tissues (Schuchardt et al., 1994) . Loss-offunction Ret mutations result in Hirschsprung's disease, a rare pediatric disorder associated with the absence of neural innervation within the gastrointestinal tract (Edery et al., 1997) . In contrast, mutational activation of Ret is linked with sporadic and inherited thyroid tumors and underlies the development of the MEN2A, MEN2B, and familial medullary thyroid cancer (FMTC) syndromes (Pasini et al., 1996; Smith et al., 1994) . To test whether the high frequency of MTC in the Rb/p53 double heterozygous mice occurred through a RET-dependent pathway, we microdissected focal MTC samples from paran embedded slides from eight dierent mice and subjected the genomic DNA to polymerase chain reaction (PCR) ampli®cation using murine Ret speci®c oligonucleotide primers. In addition, we harvested DNA from a fresh, macroscopic murine thyroid mass for genomic sequence analysis. We detected a wild type Ret allele in all samples, however, in four mice (three from microdissected paran embedded MTC specimens and one from fresh MTC tissue) we also detected mutant Ret alleles that corresponded to predicted activating missense mutations targeted to cysteine residues clustered within the extracellular RET domain that corresponded to human MEN2A Ret mutations (Figure 2 ). Each MTC sample tested (MTC 1 ± 9) were obtained from separate mice. In MTC 1 we subcloned the wild type and mutant alleles separately demonstrating a single cysteine to arginine substitution at codon 611 (corresponds to human Ret codon 609). In MTC 2 we detected both a wild type and mutant allele corresponding to a single cysteine to arginine substitution at codon 622 (corresponds to human Ret codon 620). In MTC 3 we detected a wild type and a mutant Ret corresponding to a single cysteine to serine substitution at codon 611 and in MTC 4 we subcloned the mutant allele separately and showed a single cysteine to arginine substitution at murine Ret codon 611. Each of these somatic mutations are located at cysteine residues linked with human MEN2A and are predicted to result in a constitutively activated murine RET receptor (Santoro et al., 1995) . In addition, in a separate MTC sample, MTC 5, we observed a missense mutation corresponding to an asparagine to aspartic acid substitution at codon 612 (N612D; data not shown). While it is possible that this substitution would disrupt the secondary structure of the tandem cysteines, this type of substitution has not been previously reported as an activating mutation. We also examined four MTC samples for alterations at the codon corresponding to the human M918T substitution observed in MEN2B families and we did not observe any mutations (data not shown). The absence of cysteine Ret mutations in murine MTC samples, MTC 6 ± 9, could be explained by diculties in the microdissection of small, formalin-®xed tumor nodules with surrounding normal thyroid tissue. Alternatively, we may have missed a mutation elsewhere within the RET gene or these MTC samples may have sustained mutations within alternate, parallel signal transduction pathways.
To examine if the remaining Rb allele was inactivated in these tumors, we conducted immunohistochemical staining of the tumor tissues. Paran sections were reacted with the a-RB monoclonal antibody PMG 3-245 using antigen retrieval methodology as previously described (Edery et al., 1997) . We ®rst con®rmed the absence of RB staining in two Figure 1 Tumor spectrums of Rb/p53 heterozygous mice (DbHz) (n=36) (a) and Rb heterozygous p53 homozygous mice (Rb Hz p53 Hm) (n=13) (b). The animal studies were conducted under a National Cancer Institute-approved animal study protocol. The mice (strain 129/Rb+/7 and strain 129/p53+/7) were obtained from Jackson Laboratories (Bar Harbor, Maine, USA), and mated to obtain Rb/p53 heterozygous and Rb heterozygous p53 homozygous mice. Tail DNA was isolated by incubation of tails in Proteinase K buer (100 mM Tris pH 8.5, 5 mM EDTA, 0.2% SDS, 200 mM NaCl, 100 mg/ml Proteinase K) overnight and genotyping was done by PCR analysis using previously published conditions (Jacks et al., 1992 . Necropsy was performed on mice, and paran embedded slides (American Histolabs, Inc, Gaithersburg, MD, USA) of tissues were subjected to light microscopy and microdissection for extraction of genomic DNA. Filled bars represent histologic diagnosis of cancer by hematoxylin and eosin stained light microscopy, and open bars represent histologic diagnosis of hyperplasia or adenoma by hematoxylin and eosin stained light microscopy. PIT=Pituitary carcinoma or adenoma, MTC=Medullary thyroid cancer or thyroid C-cell hyperplasia, ISLET=Islet cell tumor of the pancreas or islet hyperplasia, SARC=Sarcoma, PULM=Pulmonary adenocarcinoma or adenoma, LYMPH=Lymphoma, TER=Teratoma Figure 2 Sequencing of Ret mutations in murine MTC. Partial Ret nucleotide sequence from genomic DNA extracted from four dierent mice with medullary thyroid cancer (MTC 1 ± 4). MTC 1 shows the presence of both the wild type allele (Wt) and a mutant Ret allele at murine nucleotide 1831 (GenBank accession X67812) which were subcloned separately. C611R: cysteine to arginine substitution at codon 611; C622R: cysteine to arginine substitution at codon 622; C611S: cysteine to serine substitution at codon 611. Genomic DNA from MTC 1 ± 3 were obtained by microdissection of paran embedded tumors and extraction from the paran embedded tissue was done using a protocol for ®xed tissue as recommended by the manufacturer (Gentra Systems DNA isolation system, Minneapolis, MN, USA). MTC 4 was obtained by extraction of genomic DNA from a fresh thyroid tumor using a protocol as recommended by the manufacturer (Gentra Systems DNA isolation system). Polymerase chain reaction (PCR) conditions were as follows: 948C620 s, 608C630 s, 728C61 min 635 cycles with the ®nal extension-728C610'. Although the murine and human RET proteins have conserved the tandem cysteines of the extracellular domain, the codon coordinates dier by two residues (ie. human cysteine 609 corresponds to murine cysteine 611). The paired Ret oligonucleotides used to amplify the extracellular RET domain of the murine gene were: nucleotide coordinate 1765-sense 5'-GATCCGTGCCGACATTGTTGGA-3'; nucleotide 1883 a-sense 5'-GATCCTGGCTGTCCTCTGG-3'; nucleotide 1885-sense 5'-GATCGGCCCACTGTGTGATGCG-3'; nucleotide 2139 a-sense 5'-GATCCGGGATCTTGAAAGAGTC-3'. The ampli®ed fragments were subcloned into the pT7blue plasmid vector (Novagen, Madison, WI, USA) and small pools of transformants were subjected to nucleotide sequencing . Paran sections were subjected to an antigen retrieval step (30 min in 0.01 M citrate buer, 95 ± 1008C). They were then incubated with monoclonal antibody PMG3-245 (PharMingen, San Diego, CA, USA) at 2 mg/ml for 2 h at room temperature. The detection reaction utilized the Vector Elite ABC kit (as recommended by the manufacturer, Burlingame, CA, USA). 3.3'-diaminobenzidine was used as the chromogen, and hematoxylin as the counterstain dierent pituitary carcinoma samples isolated from the same colony of RB+/7, p53+/7 mice as previously reported (Jacks et al., 1992 and data not shown). We also observed absent RB protein expression in each MTC sample with a Ret mutation (Figure 3) . This is consistent with recent studies that showed loss of heterozygosity (LOH) of the remaining wild type Rb allele in this murine MTC model (Harvey et al., 1995; Williams et al., 1994) . Although we could not assess LOH at the p53 locus in our MTC samples due to insucient material, the previous observation that four of ®ve MTC samples from Rb+/7 p53+/7 mice showed loss of the wild type p53 allele by LOH analysis oers evidence for activation of both Rb and p53 in these murine endocrine thyroid tumors (Harvey et al., 1995) . The contribution of p53 inactivation to the development of MTC, however, is uncertain as MTC tumors have been observed in RB+/7 mice without concomitant p53 inactivation .
The observation that MTC occurs through a multistep mutational process in this murine gene knockout model raises several important points. The demonstration of activating RET mutations at the tandem cysteine domain, and not the M918T substitution seen in human sporadic MTC, may be consistent with the observation that the predisposition to the development of MTC in these mice is not analogous to human sporadic MTC. We are reluctant, however, to emphasize a direct hypothesis linking this mouse model with human disease because there is yet no clear evidence of RB inactivation in human FMTC or MEN2A, and the phenotypes of human and mouse cancer models are frequently discordant. Since somatic multi-step tumorigenesis is the hallmark of common adult malignancies, the ®nding of acquired activating Ret mutations recapitulates an essential genetic feature of human tumors and helps to validate the use of this murine gene knock-out model. Of interest, we observed that Rb+/7 p537/7 mice had signi®cantly fewer MTC (one out of 12 mice) which correlates with a reduced mouse lifespan (5 months average survival for Rb+/7 p537/7 ospring versus 7.2 months average survival for the Rb+/7 p53+/7 double heterozygote mice). Further, the single p537/7 mouse that developed MTC exceeded the average mouse lifespan by two months, suggesting a minimum time period of approximately 7 months to allow for somatic multistep mutagenesis and clonal expansion. This data, therefore, suggests that the development of murine MTC requires the cooperation of at least two independent pathways which includes the inactivation of nuclear tumor suppressor gene pathways and the activation of the plasma membrane-bound RET receptor. A plausible conclusion from this data is that other endocrine tumors observed in this murine model, such as pituitary tumors and islet cell tumors of the pancreas, may also be associated with a similar somatic, mutational multi-step process. Another provocative hypothesis that arises from this data is that the markedly dierent timing for the onset of MTC between human MEN2A and MEN2B patients may result from the requirement for an additional cooperating mutation(s) in MEN2A and FMTC families.
